Oxurion-full enrollment Phase 2 of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for treatment of DME (4.4.2019)

04 april 2019

Oxurion (ThromboGenics)

Bijlagen

Oxurion -full e...